Skip to main content
. 2024 May 5;12(5):500. doi: 10.3390/vaccines12050500

Figure A11.

Figure A11

Vaccine efficacy (VE) for respiratory syncytial virus (RSV) vaccines in older adults (age ≥ 60 years) only in serogroup B with lower respiratory tract disease (LRTD) with 3 or more signs/symptoms (I2 0.0%, 95% CI 0.0 to 89.6; tau2 0.0, 95% CI 0.0 to 10.341; Q = 0.64, p = 0.727) [51,52,81].